EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Activated immune infiltrates expand opportunities for targeted therapy in p53 ‐abnormal endometrial carcinoma

Spencer D Martin iD, Shelby Thornton, Christine Chow, Katy Milne, Juliana Sobral de Barros iD, Kayleigh A Morris, Samuel Leung, Amy Jamieson, Brad H Nelson, Dawn R Cochrane iD, David G Huntsman iD, C Blake Gilks iD und 3 weitere

The Journal of Pathology · 2025

DOI: 10.1002/path.6429 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology, 2025. Verfasst von Spencer D Martin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Faculty of Medicine, The University of British Columbia, Vancouver, Canada. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Tumor Microenvironment, Tumor Suppressor Protein p53, Lymphocytes, Tumor-Infiltrating. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Canadian Cancer Society, Terry Fox Research Institute, Canada Research Chairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor protein p53 mutated/abnormal (p53abn) endometrial carcinomas account for over 50% of deaths but comprise only 15% of all endometrial carcinomas. Most patients show limited response to standard‐of‐care chemotherapy with or without radiotherapy, and only a minority of cases are amenable to targeted therapies like poly‐ADP ribose polymerase (PARP) inhibitors and HER2‐directed therapies. Recent immunotherapy clinical trials have demonstrated remarkable efficacy, not only in mismatch repair deficient (MMRd) tumors but also in a subset of mismatch repair‐proficient (MMRp) tumors. However, the immune microenvironment and its relationship to other therapeutic targets in MMRp endometrial carcinoma remains poorly understood. Here, we characterize the immune microenvironment of p53abn endometrial carcinoma, the most clinically aggressive subtype of MMRp endometrial carcinoma, and correlate antitumor immune signatures with other targetable alterations. We accrued 256 treatment‐naïve p53abn endometrial carcinomas and systemically profiled T‐cell, B‐cell, myeloid, and tumor‐cell populations with multiplex immunofluorescence to assess the tissue localization and functional status of immune cells. Shallow whole‐genome sequencing was performed on a subset of 126 cases. Patterns of immune infiltration were compared to survival outcomes and mutational signatures. Mixture modeling divided p53abn endometrial carcinoma into tumor‐infiltrating lymphocyte (TIL)‐rich and TIL‐poor subsets. Over 50% of tumors were TIL‐rich. TIL‐rich cases overexpressed targetable immune evasion molecules and were associated with longer overall and disease‐specific survival in multivariate analysis. This effect was particularly pronounced in advanced stage disease and in patients who did not receive adjuvant chemotherapy. TIL did not associate with homologous recombination deficient mutational signatures or HER2 amplification. Our findings demonstrate a biological rationale for immunotherapy in a substantial subset of patients with p53abn endometrial cancer and may help inform combination therapies with immune checkpoint inhibition, PARP inhibitors, and anti‐HER2 agents. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsTumor MicroenvironmentTumor Suppressor Protein p53Lymphocytes, Tumor-InfiltratingBiomarkers, TumorHumansFemaleMutationMiddle AgedAgedMolecular Targeted TherapyDNA Mismatch Repair

Stichwörter der Autor:innen

HER2PARP inhibitorsendometrial cancerimmunotherapyp53abntumor microenvironmenttumor‐infiltrating lymphocytes

Substanzen

Tumor Suppressor Protein p53TP53 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, Faculty of Medicine, The University of British Columbia, Vancouver, Canada.
  • Molecular and Advanced Pathology Core (MAPcore), The University of British Columbia, Vancouver, Canada.
  • Trev and Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, Canada.
  • Department of Molecular Oncology, British Columbia Cancer Agency, The University of British Columbia, Vancouver, Canada.
  • Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The University of British Columbia, Vancouver, Canada.
  • Department of Medical Genetics, Faculty of Medicine, The University of British Columbia, Vancouver, Canada.

ORCID-Profile: Spencer D Martin, Juliana Sobral de Barros, Dawn R Cochrane, David G Huntsman, C Blake Gilks, Jessica N McAlpine, Allen W Zhang

Förderung

  • Canadian Cancer Society
  • Terry Fox Research Institute
  • Canada Research Chairs
  • BC Cancer Foundation
  • Vancouver Coastal Health Research Institute
  • VGH and UBC Hospital Foundation

Zitieren

APA

Martin, S. D., Thornton, S., Chow, C., Milne, K., de Barros, J. S., Morris, K. A., Leung, S., Jamieson, A., Nelson, B. H., Cochrane, D. R., Huntsman, D. G., Gilks, C. B., Hoang, L., McAlpine, J. N., & Zhang, A. W. (2025). Activated immune infiltrates expand opportunities for targeted therapy in p53 ‐abnormal endometrial carcinoma. The Journal of Pathology. https://doi.org/10.1002/path.6429

Vancouver

Martin SD, Thornton S, Chow C, Milne K, de Barros JS, Morris KA, et al. Activated immune infiltrates expand opportunities for targeted therapy in p53 ‐abnormal endometrial carcinoma. The Journal of Pathology. 2025. doi:10.1002/path.6429

BibTeX
@article{Martin2025,
  author = {Martin, Spencer D and Thornton, Shelby and Chow, Christine and Milne, Katy and de Barros, Juliana Sobral and Morris, Kayleigh A and Leung, Samuel and Jamieson, Amy and Nelson, Brad H and Cochrane, Dawn R and Huntsman, David G and Gilks, C Blake and Hoang, Lien and McAlpine, Jessica N and Zhang, Allen W},
  title = {Activated immune infiltrates expand opportunities for targeted therapy in p53 ‐abnormal endometrial carcinoma},
  journal = {The Journal of Pathology},
  year = {2025},
  doi = {10.1002/path.6429}
}
Kostenlos starten →